Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators

Eman A. Akam, Tsuhen M. Chang, Andrei V. Astashkin, Elisa Tomat

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Iron scavengers (chelators) offer therapeutic opportunities in anticancer drug design by targeting the increased demand for iron in cancer cells as compared to normal cells. Prochelation approaches are expected to avoid systemic iron depletion as chelators are liberated under specific intracellular conditions. In the strategy described herein, a disulfide linkage is employed as a redox-directed switch within the binding unit of an antiproliferative thiosemicarbazone prochelator, which is activated for iron coordination following reduction to the thiolate chelator. In glutathione redox buffer, this reduction event occurs at physiological concentrations and half-cell potentials. Consistent with concurrent reduction and activation, higher intracellular thiol concentrations increase cell susceptibility to prochelator toxicity in cultured cancer cells. The reduction of the disulfide switch and intracellular iron chelation are confirmed in cell-based assays using calcein as a fluorescent probe for paramagnetic ions. The resulting low-spin Fe(iii) complex is identified in intact Jurkat cells by EPR spectroscopy measurements, which also document a decreased concentration of active ribonucleotide reductase following exposure to the prochelator. Cell viability and fluorescence-based assays show that the iron complex presents low cytotoxicity and does not participate in intracellular redox chemistry, indicating that this antiproliferative chelation strategy does not rely on the generation of reactive oxygen species.

Original languageEnglish (US)
Pages (from-to)1905-1912
Number of pages8
JournalMetallomics
Volume6
Issue number10
DOIs
StatePublished - 2014

Fingerprint

Thiosemicarbazones
Chelating Agents
Disulfides
Iron
Chemical activation
Switches
Oxidation-Reduction
Cells
Chelation
Assays
Ribonucleotide Reductases
Jurkat Cells
Drug Design
Drug Delivery Systems
Cytotoxicity
Fluorescent Dyes
Sulfhydryl Compounds
Glutathione
Paramagnetic resonance
Toxicity

ASJC Scopus subject areas

  • Biomaterials
  • Metals and Alloys
  • Chemistry (miscellaneous)
  • Biochemistry
  • Biophysics
  • Medicine(all)

Cite this

Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators. / Akam, Eman A.; Chang, Tsuhen M.; Astashkin, Andrei V.; Tomat, Elisa.

In: Metallomics, Vol. 6, No. 10, 2014, p. 1905-1912.

Research output: Contribution to journalArticle

Akam, Eman A. ; Chang, Tsuhen M. ; Astashkin, Andrei V. ; Tomat, Elisa. / Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators. In: Metallomics. 2014 ; Vol. 6, No. 10. pp. 1905-1912.
@article{f69ca19af7c7456bb20e4ef869915011,
title = "Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators",
abstract = "Iron scavengers (chelators) offer therapeutic opportunities in anticancer drug design by targeting the increased demand for iron in cancer cells as compared to normal cells. Prochelation approaches are expected to avoid systemic iron depletion as chelators are liberated under specific intracellular conditions. In the strategy described herein, a disulfide linkage is employed as a redox-directed switch within the binding unit of an antiproliferative thiosemicarbazone prochelator, which is activated for iron coordination following reduction to the thiolate chelator. In glutathione redox buffer, this reduction event occurs at physiological concentrations and half-cell potentials. Consistent with concurrent reduction and activation, higher intracellular thiol concentrations increase cell susceptibility to prochelator toxicity in cultured cancer cells. The reduction of the disulfide switch and intracellular iron chelation are confirmed in cell-based assays using calcein as a fluorescent probe for paramagnetic ions. The resulting low-spin Fe(iii) complex is identified in intact Jurkat cells by EPR spectroscopy measurements, which also document a decreased concentration of active ribonucleotide reductase following exposure to the prochelator. Cell viability and fluorescence-based assays show that the iron complex presents low cytotoxicity and does not participate in intracellular redox chemistry, indicating that this antiproliferative chelation strategy does not rely on the generation of reactive oxygen species.",
author = "Akam, {Eman A.} and Chang, {Tsuhen M.} and Astashkin, {Andrei V.} and Elisa Tomat",
year = "2014",
doi = "10.1039/c4mt00153b",
language = "English (US)",
volume = "6",
pages = "1905--1912",
journal = "Metallomics",
issn = "1756-5901",
publisher = "Royal Society of Chemistry",
number = "10",

}

TY - JOUR

T1 - Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators

AU - Akam, Eman A.

AU - Chang, Tsuhen M.

AU - Astashkin, Andrei V.

AU - Tomat, Elisa

PY - 2014

Y1 - 2014

N2 - Iron scavengers (chelators) offer therapeutic opportunities in anticancer drug design by targeting the increased demand for iron in cancer cells as compared to normal cells. Prochelation approaches are expected to avoid systemic iron depletion as chelators are liberated under specific intracellular conditions. In the strategy described herein, a disulfide linkage is employed as a redox-directed switch within the binding unit of an antiproliferative thiosemicarbazone prochelator, which is activated for iron coordination following reduction to the thiolate chelator. In glutathione redox buffer, this reduction event occurs at physiological concentrations and half-cell potentials. Consistent with concurrent reduction and activation, higher intracellular thiol concentrations increase cell susceptibility to prochelator toxicity in cultured cancer cells. The reduction of the disulfide switch and intracellular iron chelation are confirmed in cell-based assays using calcein as a fluorescent probe for paramagnetic ions. The resulting low-spin Fe(iii) complex is identified in intact Jurkat cells by EPR spectroscopy measurements, which also document a decreased concentration of active ribonucleotide reductase following exposure to the prochelator. Cell viability and fluorescence-based assays show that the iron complex presents low cytotoxicity and does not participate in intracellular redox chemistry, indicating that this antiproliferative chelation strategy does not rely on the generation of reactive oxygen species.

AB - Iron scavengers (chelators) offer therapeutic opportunities in anticancer drug design by targeting the increased demand for iron in cancer cells as compared to normal cells. Prochelation approaches are expected to avoid systemic iron depletion as chelators are liberated under specific intracellular conditions. In the strategy described herein, a disulfide linkage is employed as a redox-directed switch within the binding unit of an antiproliferative thiosemicarbazone prochelator, which is activated for iron coordination following reduction to the thiolate chelator. In glutathione redox buffer, this reduction event occurs at physiological concentrations and half-cell potentials. Consistent with concurrent reduction and activation, higher intracellular thiol concentrations increase cell susceptibility to prochelator toxicity in cultured cancer cells. The reduction of the disulfide switch and intracellular iron chelation are confirmed in cell-based assays using calcein as a fluorescent probe for paramagnetic ions. The resulting low-spin Fe(iii) complex is identified in intact Jurkat cells by EPR spectroscopy measurements, which also document a decreased concentration of active ribonucleotide reductase following exposure to the prochelator. Cell viability and fluorescence-based assays show that the iron complex presents low cytotoxicity and does not participate in intracellular redox chemistry, indicating that this antiproliferative chelation strategy does not rely on the generation of reactive oxygen species.

UR - http://www.scopus.com/inward/record.url?scp=84907618316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907618316&partnerID=8YFLogxK

U2 - 10.1039/c4mt00153b

DO - 10.1039/c4mt00153b

M3 - Article

C2 - 25100578

AN - SCOPUS:84907618316

VL - 6

SP - 1905

EP - 1912

JO - Metallomics

JF - Metallomics

SN - 1756-5901

IS - 10

ER -